Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study

TAIPEI, Taiwan and SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis (NASH). NASH, a progressive liver disease closely associated with…#taipei #taiwan #sandiego #polarisgroup #nash #adipeg20 #adipeg #howardchen #pegargiminase #bla
Source: Reuters: Health - Category: Consumer Health News Source Type: news